» Articles » PMID: 25585930

A Comparative Study of Impedance Versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling

Overview
Specialty Biotechnology
Date 2015 Jan 15
PMID 25585930
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Profiling ligand function on G-protein coupled receptors (GPCRs) typically involves using transfected cells over-expressing a target of interest, a labelled ligand, and intracellular secondary messenger reporters. In contrast, label-free assays are sensitive enough to allow detection in native cells, which may provide a more physiologically relevant readout. Here, we compare four agonists (native agonists, a peptide full agonist and a peptide partial agonist) that stimulate the human inflammatory GPCR C5aR. The receptor was challenged when present in human monocyte-derived macrophages (HMDM) versus stably transfected human C5aR-CHO cells. Receptor activation was compared on label-free optical and impedance biosensors and contrasted with results from two traditional reporter assays. The rank order of potencies observed across label-free and pathway specific assays was similar. However, label-free read outs gave consistently lower potency values in both native and transfected cells. Relative to pathway-specific assays, these technologies measure whole-cell responses that may encompass multiple signalling events, including down-regulatory events, which may explain the potency discrepancies observed. These observations have important implications for screening compound libraries against GPCR targets and for selecting drug candidates for in vivo assays.

Citing Articles

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.

Huang Y, Burns D, Rich B, MacNeil I, Dandapat A, Soltani S BMC Cancer. 2017; 17(1):199.

PMID: 28302091 PMC: 5356237. DOI: 10.1186/s12885-017-3181-0.


Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.

Croker D, Monk P, Halai R, Kaeslin G, Schofield Z, Wu M Immunol Cell Biol. 2016; 94(8):787-95.

PMID: 27108698 DOI: 10.1038/icb.2016.43.


Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists.

Seow V, Lim J, Cotterell A, Yau M, Xu W, Lohman R Sci Rep. 2016; 6:24575.

PMID: 27094554 PMC: 4837355. DOI: 10.1038/srep24575.

References
1.
Manthey H, Thomas A, Shiels I, Zernecke A, Woodruff T, Rolfe B . Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011; 25(7):2447-55. DOI: 10.1096/fj.10-174284. View

2.
Prinster S, Hague C, Hall R . Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev. 2005; 57(3):289-98. DOI: 10.1124/pr.57.3.1. View

3.
Fang Y, Ferrie A, Fontaine N, Yuen P . Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal Chem. 2005; 77(17):5720-5. DOI: 10.1021/ac050887n. View

4.
Oksjoki R, Laine P, Helske S, Vehmaan-Kreula P, Mayranpaa M, Gasque P . Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis. 2007; 195(1):90-9. DOI: 10.1016/j.atherosclerosis.2006.12.016. View

5.
Skokowa J, Ali S, Felda O, Kumar V, Konrad S, Shushakova N . Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol. 2005; 174(5):3041-50. DOI: 10.4049/jimmunol.174.5.3041. View